Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Limited, has entered an exclusive co-development and commercialization agreement with Switzerland-based mAbTree Biologics AG for a breakthrough checkpoint inhibitor in immuno-oncology.
Under this partnership, Shilpa Biologicals will manage the asset’s clinical development and long-term commercial supply through GMP manufacturing. Additionally, Shilpa will facilitate market access in India and key global regions via its extensive network.
“We are delighted to enter this strategic collaboration with mAbTree Biologics as we share a common vision to bring innovative solutions to address unmet medical needs around the globe especially in the field of oncology where Shilpa has had a long history of providing affordable innovative solutions” said Mr. Madhav Bhutada, Director, Shilpa Biologicals.
The novel biologic focuses on targeting an immune checkpoint protein that enhances T-cell activation, strengthening the body’s immune response against tumors. Unlike the widely known PD-1/PD-L1 blockade, this new approach has demonstrated high therapeutic potential for treating multiple cancers, including lung cancer, head and neck squamous cell carcinoma, and hematologic malignancies.
Research suggests that this innovative therapy could convert “cold” tumors (with poor immune infiltration) into “hot” tumors (with strong immune infiltration), potentially suppress metastasis and improve responses to chemotherapy. This makes it a promising candidate for both monotherapy and combination treatments.
